Some men with prostate cancer never need treatment. For others, the disease is life-threatening. Research is now making major strides toward detecting aggressive tumors earlier and giving healthcare professionals better tools to choose the right treatment for each patient.
Prostate cancer is the most common cancer among men in Sweden. But the disease can progress in very different ways. Some men can live their entire lives with a small tumor without ever becoming ill, while others urgently need intensive treatment.
Distinguishing between these patients is one of the biggest challenges in prostate cancer research.
“We have an increasing number of effective treatments that can extend patients’ lives. But these treatments can also cause serious side effects. That’s why we need to get better at identifying which patients truly need them,” says Karin Welén, Associate Professor at the University of Gothenburg.
A nationwide research initiative
Together with Andreas Josefsson, who initiated the project, Karin Welén leads SPRINTR, a nationwide research initiative. Josefsson is an Associate Professor of Urology at the University of Gothenburg and is based in Umeå, where he works as a Senior Lecturer at Umeå University and a urologist for Region Västerbotten.
The goal is to offer every man in Sweden undergoing evaluation for prostate cancer the opportunity to participate in SPRINTR. By continuously collecting biological samples and healthcare data, the researchers aim to build a national research database that will also make it possible to invite patients to new treatment studies, regardless of where they live. So far, around 1,000 men have enrolled.
Karin Welén and Andreas Josefsson.
Photo: Göteborgs universitet
Among other things, the researchers will investigate whether tumors’ genetic characteristics, proteins, and images of tissue samples can reveal which treatments work best. Artificial intelligence could become an important tool.
“There is so much happening in research right now. I’m very hopeful that we will be able to select treatments more precisely while sparing many men unnecessary side effects,” says Karin Welén.
The same approach could also be used for other types of cancer. Plans are already underway for a parallel research initiative focusing on cancers of the liver, pancreas, and bile ducts.
Preventing cancer from spreading
In her own research, Karin Welén investigates how prostate cancer spreads to the bones. Even before cancer cells reach the bone marrow, a tumor can send signals that prepare the environment for metastases. Working with other researchers, she is trying to understand how this signaling works and whether it is possible to detect at an early stage whether the cancer is about to spread.
The researchers compare blood and bone marrow samples from patients and also conduct experiments in mice to investigate how substances released by patients’ cancer cells affect the bone marrow. Their goal is to identify early warning signs. In the longer term, they hope this could make it possible to start more intensive treatment before the cancer spreads, or to develop drugs that block the signaling.
Fewer unnecessary examinations
Meanwhile, researchers are making progress in detecting aggressive prostate cancer at an early stage. Jonas Hugosson, Professor of Urology at the University of Gothenburg, leads the long-running Gothenburg studies of prostate cancer screening. In one of these studies, 37,000 men are invited to undergo PSA testing, followed by magnetic resonance imaging (MRI) if their PSA levels are elevated.
The aim is to detect cancers that require treatment early while reducing the risk of detecting small, usually harmless tumors that can lead to unnecessary examinations and treatments. The researchers are now investigating whether this approach also reduces prostate cancer mortality and how AI could improve diagnostic accuracy.
Jonas Hugosson and Ola Bratt.
Photo: Johan Wingborg
“We know that early diagnosis reduces deaths from prostate cancer. But PSA is not perfect and can be elevated for other reasons. MRI helps us determine which men need a biopsy,” says Jonas Hugosson.
The researchers also want to examine how participating in screening affects men’s mental health and how healthcare resources can be used most effectively.
Ola Bratt, Professor of Urology at the University of Gothenburg, also conducts research on organized prostate cancer testing. His work aims to make testing more appropriate and equitable, while taking men’s mental health and social circumstances into account.
From early detection to the treatment of metastatic disease, these research efforts share a common goal: to help more men survive prostate cancer while ensuring that as few men as possible have to live with the consequences of treatment.
Prostate cancer
Around 11,000 men are diagnosed with prostate cancer in Sweden each year, and approximately 2,100 die from the disease. The risk increases with age. Prostate cancer often grows slowly and rarely causes symptoms in its early stages. A PSA blood test can raise suspicion of cancer, but elevated levels can have other causes. An MRI scan is therefore usually performed, followed by a tissue biopsy when needed to confirm the diagnosis. Treatment may involve active surveillance, surgery, radiation therapy, or medication.